Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin - PubMed (original) (raw)

Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin

S B Calderwood et al. Antimicrob Agents Chemother. 1981 Apr.

Abstract

Streptococcus faecalis strains may resist penicillin-aminoglycoside synergy by the production of plasmid-mediated aminoglycoside-modifying enzymes. One of these enzymes, aminoglycoside 3'-phosphotransferase, has been shown to have a broad range of substrate specificity, including amikacin. We have studied a derivative of amikacin, 4'-deoxy, 6'-N-methylamikacin (BB-K311), against 11 clinical blood isolates of S. faecalis. Minimal inhibitory concentrations of BB-K311 were quite similar to those of amikacin, ranging from 125 to 1,000 micrograms/ml. In assays for antibiotic synergy, penicillin and amikacin produced enhanced killing compared with the penicillin alone only against those three strains which lacked the phosphotransferase enzyme. The other eight enzyme-positive strains actually demonstrated significant antagonism between penicillin against all 11 strains, regardless of enzyme production. Analysis of substrate profiles with crude preparations of the aminoglycoside 3'-phosphotransferase enzyme confirmed that BB-K311 was a very poor substrate for modification, as expected from the synergy studies. Use of other aminoglycoside analogs confirmed the 3'-OH site of modification. These findings suggest that removing the 4'-OH group in amikacin effectively blocks 3'-phosphorylation by S. faecalis enzyme.

PubMed Disclaimer

Cited by

The life and times of the Enterococcus.
Murray BE. Murray BE. Clin Microbiol Rev. 1990 Jan;3(1):46-65. doi: 10.1128/CMR.3.1.46. Clin Microbiol Rev. 1990. PMID: 2404568 Free PMC article. Review.
A new high-level gentamicin resistance gene, aph(2'')-Id, in Enterococcus spp.
Tsai SF, Zervos MJ, Clewell DB, Donabedian SM, Sahm DF, Chow JW. Tsai SF, et al. Antimicrob Agents Chemother. 1998 May;42(5):1229-32. doi: 10.1128/AAC.42.5.1229. Antimicrob Agents Chemother. 1998. PMID: 9593155 Free PMC article.
Decreased susceptibility to 4'-deoxy-6'-N-methylamikacin (BB-K311) conferred by a mutant plasmid in Escherichia coli.
Perlin MH, Lerner SA. Perlin MH, et al. Antimicrob Agents Chemother. 1982 Jul;22(1):78-82. doi: 10.1128/AAC.22.1.78. Antimicrob Agents Chemother. 1982. PMID: 6289743 Free PMC article.
Antagonistic effect of penicillin-amikacin combinations against enterococci.
Thauvin C, Eliopoulos GM, Wennersten C, Moellering RC Jr. Thauvin C, et al. Antimicrob Agents Chemother. 1985 Jul;28(1):78-83. doi: 10.1128/AAC.28.1.78. Antimicrob Agents Chemother. 1985. PMID: 3929683 Free PMC article.
New high-content disks for determination of high-level aminoglycoside resistance in clinical isolates of Enterococcus faecalis.
Leclercq R, Bismuth R, Duval J. Leclercq R, et al. Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):356-60. doi: 10.1007/BF01962078. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1396758

References

1. J Clin Invest. 1978 Jun;61(6):1645-53 - PubMed
1. Am J Med Sci. 1969 Dec;258(6):416-30 - PubMed
1. Antimicrob Agents Chemother. 1975 Nov;8(5):564-70 - PubMed
1. Science. 1950 Mar 10;111(2880):254-6 - PubMed
1. J Lab Clin Med. 1971 May;77(5):821-8 - PubMed

Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin - PubMed (original) (raw)